Janus Henderson Group PLC Buys 665,543 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Janus Henderson Group PLC grew its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 141.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,135,100 shares of the company’s stock after acquiring an additional 665,543 shares during the quarter. Janus Henderson Group PLC owned 2.52% of Apogee Therapeutics worth $51,455,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in APGE. Barclays PLC boosted its holdings in Apogee Therapeutics by 369.2% in the third quarter. Barclays PLC now owns 365,046 shares of the company’s stock worth $21,443,000 after acquiring an additional 287,243 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Apogee Therapeutics by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock valued at $1,736,000 after purchasing an additional 1,212 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Apogee Therapeutics by 22.2% during the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company’s stock valued at $448,000 after purchasing an additional 1,796 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Apogee Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock valued at $432,000 after purchasing an additional 892 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Apogee Therapeutics by 3.4% during the fourth quarter. Rhumbline Advisers now owns 52,720 shares of the company’s stock valued at $2,388,000 after purchasing an additional 1,750 shares in the last quarter. 79.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Wedbush reaffirmed an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Finally, Citigroup initiated coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $95.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $94.60.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $39.74 on Wednesday. The stock has a market cap of $1.78 billion, a PE ratio of -16.42 and a beta of 1.70. Apogee Therapeutics, Inc. has a one year low of $26.20 and a one year high of $63.50. The stock has a fifty day moving average of $36.51 and a 200 day moving average of $41.41.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.95) EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.24. As a group, sell-side analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 2,725 shares of the stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $35.75, for a total transaction of $97,418.75. Following the completion of the sale, the insider now owns 244,448 shares in the company, valued at approximately $8,739,016. This trade represents a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the transaction, the chief executive officer now owns 1,292,987 shares of the company’s stock, valued at $38,983,558.05. This represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,175 shares of company stock worth $587,191. 36.10% of the stock is owned by corporate insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.